search
Back to results

Gabapentin Regimens and Their Effects on Opioid Consumption

Primary Purpose

Knee Osteoarthritis, Knee Pain Chronic, Opioid Use

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Gabapentin
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis focused on measuring Total Knee Arthroplasty, Neurontin, Gabapentin, Opioid Tapering

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • At least 18 years of age
  • Receiving surgery for total knee replacement (TKR)
  • Opioid naïve
  • Agrees to use tracking diary to monitor opioid consumption

Exclusion Criteria:

  • Over 75 years of age on the date of surgery
  • If female, pregnant
  • Has received investigational articles < 30 days prior to enrollment or is currently receiving investigational products or devices
  • Chronic pain syndrome
  • Taking chronic narcotics and/or taking more than 10 mg of codeine per day, any amount of Hydrocodone, over 200 mg of tramadol per day, or any other narcotics prescribed for moderate or severe pain
  • Involved in pain clinics for chronic pain, or pain that is not related to the surgical site
  • On long-term gabapentin regimen
  • Taking Lyrica or Gralise
  • Known history of depression or has been treated for depression with medication
  • Has entertained suicidal thoughts and behaviors

Sites / Locations

  • Brigham and Women's Faulkner Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Standard of Care

Postoperative Gabapentin Regimen

Arm Description

Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.

Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.

Outcomes

Primary Outcome Measures

Opioid Consumption
Mean opioid consumption, measured in mg of morphine equivalents.

Secondary Outcome Measures

Days Taking Opioids
Number of days until patients are finished consuming opioid medications after discharge.
VAS Score 1: "How Much Pain do You Feel in Your Operative Site When Resting?"
Surgical site pain. Scale 0-10, with 0 best and 10 worst
VAS Score 2: "How Much Pain do You Feel in Your Operative Site When Moving?"
Surgical site pain. Scale 0-10, with 0 best and 10 worst.
VAS Score 3: "How Well Are You Sleeping?"
Sleep quality. Scale 0-10 with 0 worst and 10 best.
VAS Score 4: "How Bad is Your Nausea?"
Nausea. Scale 0-10, with 0 best and 10 worst.
VAS Score 5: "How Satisfied Are You With Your Pain Management?"
Satisfaction. Scale 0-10 with 0 worst and 10 best.

Full Information

First Posted
November 3, 2017
Last Updated
February 1, 2021
Sponsor
Brigham and Women's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03334903
Brief Title
Gabapentin Regimens and Their Effects on Opioid Consumption
Official Title
Gabapentin Regimens and Their Effects on Opioid Consumption
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
May 15, 2018 (Actual)
Primary Completion Date
April 24, 2019 (Actual)
Study Completion Date
April 24, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the best strategy of administering gabapentin in connection with our current approach to perioperative pain management. We aim to evaluate two different adjunct gabapentin regimens given in the perioperative period, and to identify which manages patient pain more effectively and safely. In this evaluation, we will identify the quantity of patients' opioid consumption, the quality of their pain management, and the frequency and severity of any side effects they might experience. Patients who are undergoing total knee replacement (TKR) and choose to participate will be randomly assigned to a treatment group using computer-generated randomization. Patients in group 1 (the control group) will receive the standard of care as pertains to gabapentin. This consists of a single 600 mg dose of gabapentin administered to the patient approximately one to two hours before surgery, then a dose of 600 mg each morning during postoperative admission. Patients in Group 2 will receive 600 mg preoperatively, plus an additional postoperative gabapentin regimen: they will take 300 mg of gabapentin every 8 hours for 1 week, then a single nightly dose of 300 mg for another month.
Detailed Description
The purpose of this study is to determine the best strategy of administering gabapentin in connection with our current approach to perioperative pain management. We aim to evaluate two different adjunct gabapentin regimens given in the perioperative period, and to identify which manages patient pain more effectively and safely. In this evaluation, we will identify the quantity of patients' opioid consumption, the quality of their pain management, and the frequency and severity of any side effects they might experience. The target enrollment is 68. Patients who are undergoing total knee replacement (TKR) at Brigham and Women's Hospital will be informed about the study and asked whether they would like to participate. Upon agreement, a patient will sign his/her consent and will be assigned to a treatment group. Patients in group 1 (the control group) will receive the standard of care as pertains to gabapentin. This consists of a single 600 mg dose of gabapentin administered to the patient approximately one to two hours before surgery, then a dose of 600 mg each morning during postoperative admission. Patients in Group 2 will receive 600 mg preoperatively, plus an additional postoperative gabapentin regimen: they will take 300 mg of gabapentin every 8 hours for 1 week, then a single nightly dose of 300 mg for another month. Every patient being discharged from the hospital will receive from the nursing staff verbal and written instructions - the latter of which will be either printed or in electronic form - about narcotic medications. The instructions will explain when to use such medications and how to taper off their consumption. Following discharge, patients will take gabapentin as directed by their discharge instructions, and in the process track their opioid consumption on their own in their diaries. They will also document their pain, nausea and satisfaction levels according to the visual analogue scale (VAS). At the first post-operative appointment, patients' levels of opioid use will be verified and compared to the amount recorded in each diary; the actual number of tablets consumed will be compared with the documented amounts and with the prescriptions they received. Patients receiving a new prescription will also receive a matching diary for the total length of opioid treatment, including further directions on how to wean themselves off their medications. Outcome measures will be collected at both post-operative visits, the first occurring 8-10 days after surgery and the second 2-3 months following. Additional data including length of stay, postoperative complications including infection and readmission, Emergency Department visits, and routinely collected postoperative functional outcome measures (PROMs) will be recorded. The Principal Investigator (PI) will review all drug consumption data and patient-reported outcome measures with the research assistant (RA) on a monthly basis as it is collected. The PI will participate in the collection of outcome data at the first and second postoperative visits. Data which could indicate a potential complication, whether related to the study or not - such as heightened risk of adverse outcomes or non-compliance with the tracking diary - will be addressed by the PI immediately. The PI will determine if the study should be altered in any way or stopped for safety reasons. Reasons for stoppage include a rate of adverse events greater than 10% in either group. Adverse events of primary concern include: Excessive sleepiness Allergic reactions to the opioid medications or gabapentin All adverse events are recorded in an adverse event log, which will be kept by the RA throughout the study. The PI will review the data on a monthly basis, as well as whenever the RA alerts the PI to any potential adverse event. These checks will help to ensure validity and patient safety. Unanticipated problems will be reported to the PHRC in accordance with PHRC guidelines.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis, Knee Pain Chronic, Opioid Use, Opioid Dependence
Keywords
Total Knee Arthroplasty, Neurontin, Gabapentin, Opioid Tapering

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Two-arm parallel design.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
77 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of Care
Arm Type
No Intervention
Arm Description
Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
Arm Title
Postoperative Gabapentin Regimen
Arm Type
Experimental
Arm Description
Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
Intervention Type
Drug
Intervention Name(s)
Gabapentin
Other Intervention Name(s)
Neurontin
Intervention Description
600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
Primary Outcome Measure Information:
Title
Opioid Consumption
Description
Mean opioid consumption, measured in mg of morphine equivalents.
Time Frame
2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
Secondary Outcome Measure Information:
Title
Days Taking Opioids
Description
Number of days until patients are finished consuming opioid medications after discharge.
Time Frame
2-3 months following surgery (measured at second postoperative appointment).
Title
VAS Score 1: "How Much Pain do You Feel in Your Operative Site When Resting?"
Description
Surgical site pain. Scale 0-10, with 0 best and 10 worst
Time Frame
2-3 months after surgery (at 2nd postoperative appointment)
Title
VAS Score 2: "How Much Pain do You Feel in Your Operative Site When Moving?"
Description
Surgical site pain. Scale 0-10, with 0 best and 10 worst.
Time Frame
2-3 months following surgery (measured at second postoperative appointment).
Title
VAS Score 3: "How Well Are You Sleeping?"
Description
Sleep quality. Scale 0-10 with 0 worst and 10 best.
Time Frame
2-3 months following surgery (measured at second postoperative appointment).
Title
VAS Score 4: "How Bad is Your Nausea?"
Description
Nausea. Scale 0-10, with 0 best and 10 worst.
Time Frame
2-3 months following surgery (measured at second postoperative appointment).
Title
VAS Score 5: "How Satisfied Are You With Your Pain Management?"
Description
Satisfaction. Scale 0-10 with 0 worst and 10 best.
Time Frame
2-3 months following surgery (measured at second postoperative appointment).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: At least 18 years of age Receiving surgery for total knee replacement (TKR) Opioid naïve Agrees to use tracking diary to monitor opioid consumption Exclusion Criteria: Over 75 years of age on the date of surgery If female, pregnant Has received investigational articles < 30 days prior to enrollment or is currently receiving investigational products or devices Chronic pain syndrome Taking chronic narcotics and/or taking more than 10 mg of codeine per day, any amount of Hydrocodone, over 200 mg of tramadol per day, or any other narcotics prescribed for moderate or severe pain Involved in pain clinics for chronic pain, or pain that is not related to the surgical site On long-term gabapentin regimen Taking Lyrica or Gralise Known history of depression or has been treated for depression with medication Has entertained suicidal thoughts and behaviors
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wolfgang Fitz, M.D.
Organizational Affiliation
Brigham and Women's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Faulkner Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02130
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28832395
Citation
Bannister K, Qu C, Navratilova E, Oyarzo J, Xie JY, King T, Dickenson AH, Porreca F. Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain. 2017 Dec;158(12):2386-2395. doi: 10.1097/j.pain.0000000000001040.
Results Reference
background
PubMed Identifier
22159931
Citation
Ozgencil E, Yalcin S, Tuna H, Yorukoglu D, Kecik Y. Perioperative administration of gabapentin 1,200 mg day-1 and pregabalin 300 mg day-1 for pain following lumbar laminectomy and discectomy: a randomised, double-blinded, placebo-controlled study. Singapore Med J. 2011 Dec;52(12):883-9.
Results Reference
background
PubMed Identifier
20418301
Citation
Rusy LM, Hainsworth KR, Nelson TJ, Czarnecki ML, Tassone JC, Thometz JG, Lyon RM, Berens RJ, Weisman SJ. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010 May 1;110(5):1393-8. doi: 10.1213/ANE.0b013e3181d41dc2.
Results Reference
background
PubMed Identifier
23780805
Citation
Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother. 2013 Jul-Aug;47(7-8):961-9. doi: 10.1345/aph.1R751. Epub 2013 Jun 18.
Results Reference
background
PubMed Identifier
24190578
Citation
Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan;174(1):70-7. doi: 10.1001/jamainternmed.2013.11950.
Results Reference
background
PubMed Identifier
25969570
Citation
Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015 Aug;49(8):897-906. doi: 10.1177/1060028015585849. Epub 2015 May 12.
Results Reference
background
PubMed Identifier
26991615
Citation
Grant MC, Lee H, Page AJ, Hobson D, Wick E, Wu CL. The Effect of Preoperative Gabapentin on Postoperative Nausea and Vomiting: A Meta-Analysis. Anesth Analg. 2016 Apr;122(4):976-85. doi: 10.1213/ANE.0000000000001120.
Results Reference
background
PubMed Identifier
23603887
Citation
Misra S, Parthasarathi G, Vilanilam GC. The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors. J Neurosurg Anesthesiol. 2013 Oct;25(4):386-91. doi: 10.1097/ANA.0b013e31829327eb.
Results Reference
background
PubMed Identifier
17657384
Citation
Montazeri K, Kashefi P, Honarmand A. Pre-emptive gabapentin significantly reduces postoperative pain and morphine demand following lower extremity orthopaedic surgery. Singapore Med J. 2007 Aug;48(8):748-51.
Results Reference
background
PubMed Identifier
28751024
Citation
Rai AS, Khan JS, Dhaliwal J, Busse JW, Choi S, Devereaux PJ, Clarke H. Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. J Plast Reconstr Aesthet Surg. 2017 Oct;70(10):1317-1328. doi: 10.1016/j.bjps.2017.05.054. Epub 2017 Jun 9.
Results Reference
background
PubMed Identifier
27672340
Citation
Arumugam S, Lau CS, Chamberlain RS. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. J Pain Res. 2016 Sep 12;9:631-40. doi: 10.2147/JPR.S112626. eCollection 2016.
Results Reference
background
PubMed Identifier
25789237
Citation
Hassani V, Pazouki A, Nikoubakht N, Chaichian S, Sayarifard A, Shakib Khankandi A. The effect of gabapentin on reducing pain after laparoscopic gastric bypass surgery in patients with morbid obesity: a randomized clinical trial. Anesth Pain Med. 2015 Feb 1;5(1):e22372. doi: 10.5812/aapm.22372. eCollection 2015 Feb.
Results Reference
background
PubMed Identifier
25207278
Citation
Mardani-Kivi M, Mobarakeh MK, Keyhani S, Motlagh KH, Ekhtiari KS. Is gabapentin effective on pain management after arthroscopic anterior cruciate ligament reconstruction? A triple blinded randomized controlled trial. Arch Bone Jt Surg. 2013 Sep;1(1):18-22. Epub 2013 Sep 15.
Results Reference
background
PubMed Identifier
22302908
Citation
Chiu TW, Leung CC, Lau EY, Burd A. Analgesic effects of preoperative gabapentin after tongue reconstruction with the anterolateral thigh flap. Hong Kong Med J. 2012 Feb;18(1):30-4.
Results Reference
background
PubMed Identifier
21081764
Citation
Moore A, Costello J, Wieczorek P, Shah V, Taddio A, Carvalho JC. Gabapentin improves postcesarean delivery pain management: a randomized, placebo-controlled trial. Anesth Analg. 2011 Jan;112(1):167-73. doi: 10.1213/ANE.0b013e3181fdf5ee. Epub 2010 Nov 16.
Results Reference
background
PubMed Identifier
20056448
Citation
Menda F, Koner O, Sayin M, Ergenoglu M, Kucukaksu S, Aykac B. Effects of single-dose gabapentin on postoperative pain and morphine consumption after cardiac surgery. J Cardiothorac Vasc Anesth. 2010 Oct;24(5):808-13. doi: 10.1053/j.jvca.2009.10.023. Epub 2010 Jan 6.
Results Reference
background
PubMed Identifier
19713257
Citation
Ture H, Sayin M, Karlikaya G, Bingol CA, Aykac B, Ture U. The analgesic effect of gabapentin as a prophylactic anticonvulsant drug on postcraniotomy pain: a prospective randomized study. Anesth Analg. 2009 Nov;109(5):1625-31. doi: 10.1213/ane.0b013e3181b0f18b. Epub 2009 Aug 27.
Results Reference
background
PubMed Identifier
19374220
Citation
Clivatti J, Sakata RK, Issy AM. Review of the use of gabapentin in the control of postoperative pain. Rev Bras Anestesiol. 2009 Jan-Feb;59(1):87-98. doi: 10.1590/s0034-70942009000100012. English, Portuguese.
Results Reference
background
PubMed Identifier
15840990
Citation
Pandey CK, Navkar DV, Giri PJ, Raza M, Behari S, Singh RB, Singh U, Singh PK. Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study. J Neurosurg Anesthesiol. 2005 Apr;17(2):65-8. doi: 10.1097/01.ana.0000151407.62650.51.
Results Reference
background
PubMed Identifier
14982565
Citation
Dierking G, Duedahl TH, Rasmussen ML, Fomsgaard JS, Moiniche S, Romsing J, Dahl JB. Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta Anaesthesiol Scand. 2004 Mar;48(3):322-7. doi: 10.1111/j.0001-5172.2004.0329.x.
Results Reference
background
PubMed Identifier
16846695
Citation
Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain--a systematic review of randomized controlled trials. Pain. 2006 Dec 15;126(1-3):91-101. doi: 10.1016/j.pain.2006.06.018. Epub 2006 Jul 18.
Results Reference
background
PubMed Identifier
21232979
Citation
Ucak A, Onan B, Sen H, Selcuk I, Turan A, Yilmaz AT. The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2011 Oct;25(5):824-9. doi: 10.1053/j.jvca.2010.11.017. Epub 2011 Jan 12.
Results Reference
background
PubMed Identifier
19547761
Citation
Clarke H, Pereira S, Kennedy D, Gilron I, Katz J, Gollish J, Kay J. Gabapentin decreases morphine consumption and improves functional recovery following total knee arthroplasty. Pain Res Manag. 2009 May-Jun;14(3):217-22. doi: 10.1155/2009/930609.
Results Reference
background
PubMed Identifier
27265421
Citation
Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016 Jul;111(7):1160-74. doi: 10.1111/add.13324. Epub 2016 Mar 18.
Results Reference
background
PubMed Identifier
15845693
Citation
Menigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg. 2005 May;100(5):1394-1399. doi: 10.1213/01.ANE.0000152010.74739.B8.
Results Reference
background

Learn more about this trial

Gabapentin Regimens and Their Effects on Opioid Consumption

We'll reach out to this number within 24 hrs